Average ticket size climbed across the board-seed by 11%, Series A by 20% and Series B by 19%. Grail Bio’s Series B round of $900M and Guardant Health’s Series E round of $360M are top investments made in this space till date.
16 companies have taken the public route in the last three years as 16 acquisitions have taken place in this sector till date.
Molecular Diagnostics with investments worth $4.8B has historically been the most funded business model followed closely by point-of-care diagnostics ($4.2B). Dollars to the tune of $3.5B have been invested in this sector between 2016-17.
Note: You can download the part view of the report here. The full version of this report is available for our paid subscribers. Should you want to access the complete report and explore the Tracxn platform, drop us a note on email@example.com